Figure 4.

OVA-BiP hybrid peptide/hsp70 complex induces significant protection against challenge with tumor cells. Mice, 8–10 per group, were challenged intradermally with 10⁶ MO4 cells after no treatment (a) or 1 week after a single immunization with hsp70 and OVA peptide (b), OVA peptide alone (c), OVA-BiP hybrid peptide alone (d), TiterMax (TM) + OVA (e), or hsp70 + OVA (f). Results are shown for individual tumor growth of each mouse as mean tumor diameter. The proportion of surviving mice in each group is shown after tumor challenge (g).